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Background: Both severe stenosis and completed occlusion in internal carotid artery or its distal branches have
been considered the main reasons of cerebral hypoperfusion, which contributes to the washout disturbances of
embolism in low perfusion territories distal to stenosis. An aggravated hypoperfusion state in certain brain region
may induce ischemic stroke and further cognitive decline. However, the effective medication for cerebral
hypoperfusion is largely unsettled.
Methods/design: By using computed tomography perfusion (CTP) imaging, the trial will evaluate the effectiveness,
safety and tolerability of hydroxyethyl starch (HES) 130/0.4 for patients with extra-/intra-cranial artery stenosis and
cerebral hypoperfusion. From 5 neurological inpatient wards, 300 patients will be randomly recruited for
administered routine medications plus intravascular volume therapies using the equal volume of HES 130/0.4 or
0.9% sodium chloride solution. Cerebral hypoperfusion state after 7-day intervention is the primary outcome
measure. The secondary outcome measures includes, impaired renal function, abnormal heart function,
hematological changes, neurological dysfunctions and cerebrovascular events in peri-intervention period and/or
3-month follow-up. The sample size will allow the detection of a two-sided 5% significance level between groups
in the endpoint with a power of 80%.
Discussion: The trial would provide important efficacy and safety data on the intravascular administration of
HES 130/0.4 in patients with unilateral cerebral hypoperfusion. The effects on kidney function, heart function,
coagulation, neurological function and cerebralvascular events will be assessed.
Trial registration: ClinicalTrials.gov (Identifier: NCT01192581)Background
Large-artery stenosis-induced cerebral hypoperfusion
As a subtype of the TOAST or CISS classification for
ischemic stroke [1,2], large-artery atherosclerosis com-
monly induces internal carotid artery (ICA) or its distal
branches (middle cerebral artery, MCA) stenosis. Severe
artery stenosis is the major prognostic stroke risk factor
in patients with symptomatic and asymptomatic ICA/
MCA disease, and would place hemodynamic stress
on the brain circulation. Among asymptomatic patients,* Correspondence: zhaogang@fmmu.edu.cn
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reproduction in any medium, provided the orincreasing frequencies of transient ischemic attack (TIA)
and stroke is related to grades of arterial stenosis. In
patients with symptoms including transient monocular
blindness, TIA and minor strokes, stroke risk highly re-
lated with the severity of ICA/MCA stenosis [3,4].
Cerebral hypoperfusion is deemed as an important ori-
gin contributed to ischemic stroke or reversible neuro-
logical dysfunctions in patients with extra-/intra-cranial
arterial stenotic or occlusive disease [5]. Large-artery-sten-
osis induced cerebral hypoperfusion leads to blockage in
smaller distal artery, which would decrease perfusion in
the local region. In some cases, embolic materials from
proximal artery might appear washout disturbances to in-
crease the degree of artery stenosis. A prolonged failure to
deliver oxygen and sugar-rich blood to brain tissue causes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions, irreversible cells death, i.e. cerebral infarction.
Management of cerebral hypoperfusion
Treatments of ICA/MCA stenosis and secondary stroke-
prevention related to intracranial arteries atherosclerosis
have been extensively explored under numbers of inves-
tigations [6]. However, enough importance has not been
attached to the management of cerebral hypoperfusion
yet. It is well known that tPA is almost the only effective
treatment for patients with acute ischemic stroke, which
improves the perfusion state of ischemic penumbra by
dissolving the blood clot. Because of the narrow thera-
peutic window, the use of tPA is largely restricted. Apart
from this, antiplatelet therapy, statins therapy and risk
factor modifications, as routine medications, are recom-
mended for patients with large-artery atherosclerosis. In
invasive treatments, carotid endarterectomy (CEA) is re-
commended for symptomatic patients with moderate to
high grade stenosis (50%–99%). Carotid angioplasty and
stenting (CAS) has been indicated as a therapeutic alter-
native to CEA [7,8], which exerts improving perfusion
state in cerebral hypoperfusion region [3,9]. However,
the role of CAS remains uncertain and controversial for
the asymptomatic patients with ICA stenosis. Recently,
researchers reported an anti-migraine agent, lomerizine,
could contribute to restoration of cerebral hypoperfu-
sion by SPECT [10].
Theoretically, volume therapy attempts to improve ce-
rebral perfusion of ischemic regions through optimiz-
ation of hemorheological parameters and increment in
cardiac output and blood pressure [11,12]. A previous
study [13] confirmed the safety of hypervolemic therapy;
however, the sample size was too small to show the cli-
nical efficacy statistically. Furthermore, unfavorable re-
sults of volume therapy in acute ischemic stroke was
reported by a meta-analysis [14] on survival or neuro-
logical function evaluation in 18 clinical trials. During
recent decades, colloidal solutions are extensively used
in the volume therapy of ischemic stroke in many coun-
tries [15]. However, the effect of medication on non-acute
cerebral hypoperfusion state is still largely unsettled.
The clinical effects of hydroxyethyl starches
Hydroxyethyl Starches (HES) is one of the worldwide-
used colloidal solutions for decreasing hematocrit and
whole-blood viscosity without significant effects on plas-
ma viscosity and red-cell aggregation [16]. HES is classi-
fied according to the molecular weight (MW) into high
MW (450±480 kDa), medium MW (130–200 kDa), and
low MW (40–70 kDa) starch preparations, which exert
different therapeutic and adverse effects respectively.
In comparison with other starch preparations, HES
130/0.4 marked for the indication ‘intravascular volumeexpansion and hemodilution’ in worldwide (Summary of
Product Characteristics for Voluven, Fresenius Kabi) and
showed advantages in the brain, such as an improvement
of hemorheologic parameters, an earlier increase of
tissue oxygen tension and a safety in large-dose infu-
sion [17,18]. Mammalian study [19] further indicated
that HES 130/0.4 played an anti-inflammatory role in
non-brain tissues. However, the effect of HES 130/0.4
on cerebral hypoperfusion state is still unclear.
Objectives of the study
The objectives of this study are to evaluate the effective-
ness, safety and tolerability of consistent dosages of HES
130/0.4 administrated intravenously for 7 days in pa-
tients with cerebral hypoperfusion in unilateral ICA or
MCA territory. We expect that the results will indicate
the effect of HES 130/0.4 on cerebral hypoperfusion.
Methods/design
Participants
Total 300 inpatients will be recruited through 5 neur-
ology wards of general hospitals in Xi’an, China. Three
subtypes of patients will be enrolled: I, non-acute ische-
mic stroke (time of stroke onset: 72 hours to 3 weeks);
II, TIA with cerebral hypoperfusion; III, asymptomatic
cerebral hypoperfusion. Outpatients showed abnormal
results in carotid color Doppler and transcranial Doppler
(temporal bone window) in routine physical examin-
ation, would be enrolled as asymptomatic candidates for
further evaluation of cerebral perfusion state.
Prior to data collection, ethics approval have been
achieved through the Medical Ethical Reviewing Com-
mittee of the Fourth Military Medical University Medical
Center. Informed consent will be supported by a patient
(or next to kin) information leaflet in Chinese. A con-
sulted meeting will be developed by a study physician to
ensure patients and their families understand the study
procedure and consent to participation in the trial [20].
Study design
Multicenter, randomized, paralleled, double-blinded trial
with concealed allocation of patients with cerebral hypo-
perfusion 1:1 to volume therapy using 6% HES 130/0.4 in
0.9% sodium chloride (Voluven, Fresenius Kabi, Germany)
or 0.9% sodium chloride solution (normal saline, NS), is
stratified by presence of stroke or not. We use digital sub-
traction angiography (DSA) to verify the severity of ICA
or MCA stenosis [21], and evaluate cerebral hypoperfu-
sion in unilateral intracranial artery territories by time to
peak (TTP), one of parameters in CTP imaging [22].
Sample size estimates
The results from our preliminary study were used to cal-
culate the sample size (unpublished data). The mean
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0.4 were 19.83 and 10.21, respectively. A two-sided 5%
significance level and 80% power were considered, and
the following equation was used:
n ¼ 2 ζα=2 þ ζβ
 2  σ2
δ2
Approximately 60 participants in each group were cal-
culated to be required. A 20% attrition rate is anticipated
over the 2-year study period, resulting in about 300 par-
ticipants in total four groups as a final estimated sample
size.
Randomization procedures
Random number will be generated by a computerized
random-number generator at statistics research office,
Fourth Military Medical University. A clinical research
associate will make opaque blinded envelopes (with con-
secutive numbers) and deliver them to each participating
center. Random allocation will be performed within 12
hour after a patient enrolled. The block size and treat-
ment-assignment table will not be available to the re-
searchers until the end of the trial.
Inclusion criteria
All patients presenting to the study center are eligible
for inclusion in the study if they fulfill the following
requirements:
1. Age: 18 to 75 years
2. The degree of ICA/MCA stenosis is greater or equal
to 50% confirmed by DSA
3. Before HES treatment, CTP imaging shows that TTP
in MCA territory is extended (≥15%) in comparison
with that in corresponding area of contralateral
hemisphere
4. If cerebral infarction appears,① Time of stroke onset: 72 hours-3 weeks
②Magnetic resonance imaging (MRI) + diffusion
weighted imaging (DWI) shows ischemic stroke
due to unilateral ICA or MCA stenosis infarcts
③NIH stroke scale: 3–20
5. Written consent obtained from patient or the proxy
Exclusion criteria
Patients are excluded from the study if they met any of
the following criteria:
1. Allergy to the components of HES
2. Clinical features including severe dehydration,
overhydration and hydrocephalus3. Chronic liver disease (ALT > 120 or AST > 120)
4. Chronic renal disease (Scr > 150 μmol/L)
5. Severe heart failure which correspond to NYHA
heart failure classification class III or IV, or serious
arrhythmia, myocardial infarction
6. Intracranial hemorrhage or structural brain lesions
which can mimic stroke (e.g. cerebral tumor) by CT
or MRI brain scanning.
7. Pregnant and lactating women
8. Patients suffered from epilepsy or mental sickness
9. Alcoholism or drug abuse
10. HES or other artificial colloidal solution was used
within 3 months.
11. Patients participate in other clinical trial within
6 months
12. Contraindication to CT perfusion imaging
(i.e. contrast allergy, metformin use or
Creatinine >160 μmol/l)
13. Thrombus in lower limb vein
Primary outcome measure
The alternation of TTP in CTP image defined as cere-
bral hypoperfusion-improvement 7 days after volume the-
rapy will be the primary outcome measure.
Secondary outcome measures
1. Cardiac-/cerebral-vascular events in three-months
2. Impaired kidney function after randomization
3. Impaired heart function at 3-day and 7-day after
randomization
4. Blood-coagulation changes at 7-day after
randomization
5. Neurological function scores (Table 1) at 7-day and
3-month after randomization
Study procedures
Figure 1 shows the trial procedure. Participants with sus-
pected unilateral ICA or MCA stenosis will firstly receive
CT and CTP brain scanning to exclude the intracranial
hemorrhage and be confirmed their cerebral perfusion
state. Patients with unilateral cerebral hypoperfusion will
be further evaluated by physicians in participating hos-
pitals according to a series of evaluation procedure,
including history taking, complete physical examination,
radiology tests and relative laboratory tests (Table 1). For
radiology tests, MRI brain scanning will be applied to con-
firm whether a consistent infarct exist in hypoperfusion
region or not, and DSA will be performed to determine
the degree of artery stenosis/occlusion. Once a standar-
dized, structured interview is performed, the data will be
recorded in the case report form for each patient. All clin-
ical data, biological samples and radiological images would
be sent to the central study site where a cerebrovascular
Table 1 Outcome variables and assesment schedule
Outcome variables Baseline Intervention period Post-intervention 3 month




Symptoms (Neuro-check) ✓ ✓ ✓ ✓
Blood pressure ✓ ✓ ✓ ✓
ECG ✓ ✓ ✓
DEC ✓ ✓
Blood/plasma viscosity ✓ ✓ ✓
Blood coagulation profile ✓ ✓ ✓ ✓
CCr ✓ ✓ ✓
Lipid profile ✓ ✓ ✓
MMSE ✓ ✓ ✓
Patients With Stroke NIHSS ✓ ✓ ✓
BI ✓ ✓ ✓
mRS ✓ ✓ ✓
ECG, Electrocardiogram; DEC, Doppler Echocardiography; CCr, Creatinine clearance; MMSE, Mini-mental State Examination; NIHSS, National Institutes of health
Stroke Scale, BI, Barthel Index; mRS, modified Rakin Scale.
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non-acute ischemic stroke, National Institutes of Health
Stroke Scale, Barthel Index and modified Rakin Scale will
be performed by an individual researcher. Demographic,
medical, social, and behavioral variables will be determinedFigure 1 Flowchart outlining the trial protocol.along with baseline medications. Anthropometry will be
conducted using standardized equipment calibrated on a
daily basis.
Participants will be randomized to one of two inter-
ventions: HES 130/0.4 and NS with two daily dosages in
each intervention, i.e. 500 ml and 1000 ml, for 7 conse-
cutive intervention days. A range of outcome measures
(Table 1) will be used to ensure evaluation of relevant
variables, based on the primary and secondary aims of
the trial, clinical relevance and feasibility. Patients will
be enrolled initially in the 500 ml groups. If more than
30% patients experience intolerable adverse events, the
trial should be stopped. Following successful completion
of 500 ml dose study, patients should be enrolled in the
1000 ml groups.
According to our preliminary study, 60% (15/25) of
patients were found infarct responsible focuses in MCA
territory by MRI brain scanning. To ensure comparable
groups in terms of neurological status, group assignment
will be stratified by having infarct responsible focuses or
not. An individual not associated with the trial will use a
computerized random number generator to randomly
assign subjects to group. Allocation concealment will be
ensured by using opaque, a sealed envelope containing
group assignment.
Intervention
All participants will receive routine medications includ-
ing antiplatelet therapy, statins therapy, risk factor modi-
fication and others if necessary. Intervention group will
receive a prescribed dose of 0.6% HES 130/0.4 in 7 inter-
vention days. Control group will be treated the same
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initial 10–20 ml will be infused slowly, keeping the pa-
tient under close observation.
Although, the infusion dose of HES 130/0.4 up to 33
mL/kg/day is most commonly used in clinical trials and
repetitive large doses of up to 70 ml/kg/day have been
reported in the literatures [23-26]. Considering potential
risks of overloading the circulatory system and increas-
ing brain edema by overdose and the median cumulative
HES dose (2465 ml, range 328 ml to 6229 ml) in resusci-
tation [27], two dose groups (500 ml/day and 1000 ml/
day) have been chosen as cumulative dose of 3500 ml
and 7000 ml.
Statistical analysis
Data will be exported into SPSS V15.0 software for subse-
quent analyses. A statistical analysis plan will be drafted
at the start of the project and all analyses will be carried
out after masking allocation. Independent samples t-tests,
Mann–Whitney U tests and Chi-square test of association
will be used as appropriate to compare groups at baseline.
ANOVA or logistic regression will be used to determine
significance of the results obtained.
Discussion
Because of the lack of reliable clinical data, the effect
of volume therapy (HES 130/0.4) on cerebral hypoper-
fusion due to severe ICA/MCA stenosis or occlusion is
largely unsettled. In this trial, three types of patients
with cerebral hypoperfusion will be recruited: non-acute
ischemic stroke, TIA and asymptomatic patients. Al-
though volume therapy could possibly decrease blood
viscosity and may increase cerebral perfusion or oxygen
delivery, previous studies [13,24,28] focused on acute is-
chemic stroke with treatment windows from 6 hours to
48 hours resulted no improvement in outcome or sur-
vival at the endpoints. In this trial, we’d like to enroll
patients with non-acute ischemic stroke (time of stroke
onset: 72 hours to 3 weeks) for the following reasons:
1. variable cerebral hypoperfusion state and higher risk
of hemorrhagic transformation may appear in patients
with acute ischemic stroke (< 72hours); 2. from 72 hours
to 3 weeks of stroke onset, patients’ emotional state and
cerebral auto-regulation are relatively stable. Cerebral
hypoperfusion with severe intracranial atherosclerosis is
one of common causes of ischemic stroke and TIA. Un-
less the collateral blood supply is sufficient to prevent is-
chemia, multiple remote spot-like infarctions may occur
within the hypoperfused brain territory. Certainly, the
superiority of surgical interventions over medical ther-
apy has been confirmed in symptomatic patients with
severe ICA stenosis [8,29]. However, for the asymptom-
atic patients with severe or moderate ICA stenosis, the
role of surgical interventions remains uncertain. For thepatients with ICA or MCA occlusion, medication could
be the only practical therapy. Unfortunately, few effec-
tive medical treatments have been developed for the
treatment of cerebral hypoperfusion. In this trial, we will
use NS as control to compare the effect of HES 130/0.4
on the improvement of cerebral hypoprefusion in MCA
territory. By using CTP imaging to confirm the brain
perfusion state [30], this trial will contribute to study the
effectiveness, safety and tolerability of safety of HES
130/0.4 for patients with chronic cerebral hypoperfusion.
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